America’s Changing Birth Rate and the Future of Family Planning: What’s Really Happening?

The Numbers Tell a Story We Need to Understand

America welcomed 3.6 million babies in 2025—a number that might sound impressive until you realize it represents yet another decline in our nation’s birth rate. According to the Centers for Disease Control and Prevention, births dropped by 1% from the previous year, continuing a downward trend that’s been worrying policymakers and demographers alike. Perhaps even more striking is the fertility rate itself: just 53.1 births per 1,000 women of childbearing age (15-44 years old), marking a dramatic 23% plunge since 2007. This isn’t just a statistical blip—it represents a fundamental shift in how American families are being formed, or in some cases, not formed at all. President Trump has made reversing this trend a priority, calling for “a new baby boom” and asking his team to explore everything from direct cash bonuses for having babies to expanded fertility planning services. But the administration’s approach to solving this complex problem has sparked intense debate, particularly around their proposed changes to Title X, the federal government’s primary family planning program that has quietly served millions of low-income Americans for more than fifty years.

Title X: From Family Planning to Something Completely Different

For over five decades, Title X has operated with a clear, bipartisan mission: providing low-income women with access to contraception, testing for sexually transmitted infections, and essential reproductive healthcare, regardless of their ability to pay. At its peak, this safety net program served more than 5 million patients annually, with six out of ten clients reporting it as their only source of healthcare in a given year. That’s not just a statistic—it represents millions of real women who depended on this program for their basic health needs. But in early April, when the Department of Health and Human Services released its 67-page invitation for organizations to apply for Title X grants for fiscal year 2027, something fundamental had changed. The document mentioned contraception exactly once—and not in a positive light. Instead, it described birth control as “overprescribed,” highlighted its negative side effects, and lumped it together with what the administration calls an “overreliance on pharmaceutical and surgical treatments.” The new focus? Fertility, family formation, and treating reproductive health conditions like polycystic ovary syndrome, endometriosis, low testosterone, and erectile dysfunction. While the program will still help women “achieve healthy pregnancies,” the grant document conspicuously avoids mentioning preventing unintended pregnancies—something that’s been a cornerstone goal of Title X since President Nixon signed it into law in 1970. Jessica Marcella, who ran the Title X program during the Biden administration, didn’t mince words about what she sees happening: “What we’re seeing is trying to use our nation’s family planning as a Trojan horse for an entirely different agenda.”

Why Are Birth Rates Really Declining? (Hint: It’s Not About Birth Control Access)

The Trump administration is reshaping Title X within the context of declining birth rates, but here’s where things get interesting: researchers who actually study fertility trends say the decline has very little to do with contraception access, and restricting birth control is highly unlikely to result in more babies being born. So what’s really going on? According to Alison Gemmill, a demographer at UCLA, the most important factors are all about timing. “Childbearing is increasingly delayed as part of a broader shift toward later adult milestones, including stable employment, leaving the parental home, and marriage,” she explains. Young adults today are taking longer to establish themselves financially, find stable housing, and feel ready for the responsibilities of parenthood. Most American women, Gemmill notes, still end up having an average of two children by the time they complete their childbearing years—suggesting we’re seeing a shift toward smaller families and delayed parenthood rather than women choosing not to have children at all. Philip Cohen, a sociology professor at the University of Maryland, reinforces this point: “The average number of babies women are having in their whole lives has not fallen. It’s still more than 2.0 for women aged 45.” In other words, much of the decline since 2007 reflects women postponing births rather than forgoing them entirely. Phillip Levine, an economist at Wellesley College, takes this analysis even further, pointing to broader shifts in how women approach work, leisure, and parenting. “Efforts to reverse those patterns would be more successful if they can make childbearing more desirable, not make it harder to prevent a pregnancy,” he argues. This perspective suggests that if policymakers genuinely want to increase birth rates, they should focus on things like affordable childcare, paid family leave, housing affordability, and economic security—not restricting access to contraception.

Two Competing Visions Collide Over Women’s Healthcare

Jessica Marcella sees the new Title X funding notice as the product of two powerful forces colliding: the “Make America Healthy Again” movement, with its deep skepticism of conventional medicine and emphasis on lifestyle and behavioral interventions, and a pronatalist agenda determined to boost birth rates by steering policy toward encouraging family formation. The document’s language clearly reflects both influences, repeatedly invoking concepts like “optimal health” and “chronic disease” while systematically sidelining the contraceptive services that have defined Title X for half a century. Clare Coleman, who leads the National Family Planning & Reproductive Health Association representing health professionals focused on family planning, argues that tying Title X to birth-rate goals fundamentally replaces individual decision-making with a government objective. The program, she insists, “is designed to facilitate access to family planning services, including services to achieve and prevent pregnancy.” But conservatives welcome these changes enthusiastically. Emma Waters, a senior policy analyst at the Heritage Foundation who has advocated for what she calls “restorative reproductive medicine,” says the new funding notice reflects long-overdue attention to neglected aspects of women’s health. “I was particularly encouraged to see language that spoke to the delays in diagnosis for conditions like endometriosis, the need for women to practically understand how their cycle and fertility works, and to ensure that real root-cause was promoted through Title X,” Waters said. She describes the notice as an expansion, not a narrowing, of the program’s mission, arguing that “the goal was never just ‘more contraception’ but a wholesale empowerment of women to govern their own fertility.” Waters also suggests that untreated reproductive health problems may actually contribute to lower birth rates, pointing particularly to endometriosis, which affects an estimated 5%-10% of women of reproductive age, with 30%-50% of those affected experiencing infertility.

The Contradictions and Complications Nobody’s Talking About

Here’s where the administration’s approach runs into some serious logical problems. While it’s true that endometriosis can cause fertility problems, the relationship between the condition and infertility is more complicated than it might seem—it’s an association, not a proven direct cause. Women aren’t screened for endometriosis unless they have symptoms, the condition may be more common than currently recognized, researchers still don’t fully understand why some women with endometriosis struggle to conceive while others don’t, and treating the disease doesn’t reliably restore fertility. Perhaps most importantly, infertility rates in the United States haven’t actually risen. An analysis of federal survey data found them essentially flat between 1995 and 2019, even as the national birth rate fell sharply—a divergence that strongly suggests untreated reproductive disease isn’t the explanation for declining births. Meanwhile, the American College of Obstetricians and Gynecologists issued new clinical guidelines in February enabling earlier diagnosis of endometriosis without surgery, directly addressing the diagnostic delays Waters described. But here’s the contradiction: the first-line treatment ACOG recommends is hormonal therapy—the exact same category of care the funding notice dismisses as part of an “overreliance on pharmaceutical and surgical treatments.” Title X is now prioritizing diagnosis of endometriosis while simultaneously deemphasizing the drugs clinicians actually use to treat it. Furthermore, treatments that have been shown to improve fertility in women with endometriosis, such as laparoscopic surgery and in vitro fertilization, aren’t even covered by Title X. Liz Romer, a former chief clinical adviser for the HHS Office of Population Affairs who helped write updated guidelines for the family planning program, acknowledges that many of the conditions prioritized in the funding notice deserve attention, but argues they fall outside what Title X can realistically provide. “There’s not even enough funding to support the core premise of contraception,” Romer said. “And so, if you want to expand Title X funding, you can expand the scope, but you can’t move away from the foundation.”

The Real-World Consequences for Women and Families

The stakes in this policy debate aren’t abstract—they’re literally life and death. The United States already has one of the highest maternal mortality rates among wealthy nations, with 17.9 deaths per 100,000 live births as of 2024. According to the CDC, four out of five pregnancy-related deaths in the U.S. may be preventable. Medical research consistently shows that pregnancy itself carries substantially higher risks of blood clots, stroke, and cardiovascular complications than hormonal contraception—a fact that makes restricting birth control access particularly concerning from a public health perspective. The landscape has become even more complex since the Supreme Court’s Dobbs decision in 2022 overturned Roe v. Wade, significantly curtailing access to abortion across much of the country. While national abortion numbers have risen overall, driven largely by telehealth and interstate access, research shows births have increased in states with bans, with an estimated 32,000 additional births annually, disproportionately affecting young women and women of color. Dr. Christine Dehlendorf, who directs the Person-Centered Reproductive Health Program at the University of California-San Francisco, stated bluntly that “there is absolutely no evidence for any positive outcome of restricting access to contraception.” Such restrictions, she warns, would instead increase demand for abortion care and make it harder for women to prevent high-risk pregnancies. The practical impact is already being felt on the ground. Since Trump returned to office, more than a dozen Title X grantees have had their grants frozen, forcing some health centers to stop delivering services, lay off staff, or close their doors entirely. During the first Trump administration, regulatory changes led to a dramatic decline in Title X participation from more than 4 million patients to just 1.5 million. The program recovered slowly under the Biden administration, reaching about 3 million clients, before the current round of disruptions began. Laura Lindberg, director of the Concentration in Sexual and Reproductive Health, Rights and Justice at Rutgers School of Public Health, warns that “if contraception is sidelined in Title X, it won’t just change language on paper but will show up as fewer options and more barriers for patients.” She predicts funding could shift away from providers offering comprehensive contraceptive care toward organizations ideologically opposed to contraception that don’t deliver the same standard of healthcare services. This matters because eight in ten women of childbearing age surveyed by KFF in 2024 reported having used some form of contraception in the previous year—meaning the emergence of what amounts to an anticontraception ideology within federal health policy stands in stark contrast to what the vast majority of American women actually want and need. As Marcella concluded, the administration’s overhaul “directly undermines the public health intent of our nation’s family planning program and will potentially exclude millions of individuals from getting the care they have relied on for decades. It’s bad policy.” The question now is whether policymakers will listen to the research, the healthcare providers on the front lines, and most importantly, the millions of women whose health and futures hang in the balance.